BRAF (V599E)

BRAF · Variant type: point · HGVS: p.V599E

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Dabrafenib	99.6%	0.4%	94.74
2	Sorafenib	99.0%	1.0%	96.72
3	Ponatinib	98.7%	1.3%	78.23
4	Regorafenib	98.7%	1.3%	95.99
5	Ripretinib	98.7%	1.3%	92.95
6	Encorafenib	98.6%	1.4%	98.50
7	Vemurafenib	96.6%	3.4%	96.49
8	Apatinib	95.9%	4.1%	97.73
9	Dasatinib	94.0%	6.0%	87.97
10	Erdafitinib	90.5%	9.5%	95.71
11	Nilotinib	89.7%	10.3%	96.49
12	Pazopanib	80.9%	19.1%	97.49
13	Umbralisib	77.3%	22.7%	98.74
14	Rabusertib	70.8%	29.2%	98.74
15	Upadacitinib	65.5%	34.5%	97.98
16	Gedatolisib	63.0%	37.0%	99.75
17	Pacritinib	59.9%	40.1%	88.64
18	Imatinib	52.4%	47.6%	99.00
19	Dacomitinib	48.4%	51.6%	97.99
20	Canertinib	47.8%	52.2%	96.49
21	Osimertinib	42.0%	58.0%	97.24
22	Tivozanib	40.4%	59.6%	92.42
23	Vandetanib	33.5%	66.5%	95.74
24	Deucravacitinib	30.4%	69.6%	98.99
25	Repotrectinib	29.2%	70.8%	84.21

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Dabrafenib	99.6%	98.3%	+1.3%
Sorafenib	99.0%	98.5%	+0.5%
Ponatinib	98.7%	99.4%	-0.7%
Regorafenib	98.7%	98.3%	+0.4%
Ripretinib	98.7%	100.0%	-1.3%
Encorafenib	98.6%	98.0%	+0.6%
Vemurafenib	96.6%	92.8%	+3.8%
Apatinib	95.9%	94.1%	+1.8%
Dasatinib	94.0%	80.6%	+13.4%
Erdafitinib	90.5%	54.1%	+36.4%
Nilotinib	89.7%	85.8%	+3.9%
Pazopanib	80.9%	79.3%	+1.6%
Umbralisib	77.3%	65.3%	+12.0%
Rabusertib	70.8%	41.1%	+29.7%
Upadacitinib	65.5%	49.6%	+15.9%
Gedatolisib	63.0%	56.5%	+6.5%
Pacritinib	59.9%	58.5%	+1.4%
Imatinib	52.4%	—	—
Dacomitinib	48.4%	46.6%	+1.7%
Canertinib	47.8%	40.7%	+7.1%
Osimertinib	42.0%	—	—
Tivozanib	40.4%	41.8%	-1.4%
Vandetanib	33.5%	—	—
Deucravacitinib	30.4%	—	—
Repotrectinib	29.2%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 15.2ms